Patent: 9,326,974

« Back to Dashboard

Summary for Patent: 9,326,974

Title:	Methods and related compositions for the treatment of cancer
Abstract:	A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.
Inventor(s):	Thompson; Todd A. (Albuquerque, NM), Mackenzie; Debra (Albuquerque, NM), Oprea; Tudor I. (Albuquerque, NM), Sklar; Larry A. (Albuquerque, NM), Edwards; Bruce S. (Albuquerque, NM), Haynes; Mark (Albuquerque, NM)
Assignee:	STC.UNM (Albuquerque, NM)
Application Number:	14/449,957
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Details for Patent 9,326,974

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source
Merck	ELSPAR	asparaginase	VIAL	101063	001	1978-01-10	➤ Sign Up	STC.UNM (Albuquerque, NM)	➤ Sign Up	RX		search
Schering	INTRON A	interferon alfa-2b	VIAL	103132	001	1986-06-04	➤ Sign Up	STC.UNM (Albuquerque, NM)	➤ Sign Up	RX		search
Schering	INTRON A	interferon alfa-2b	VIAL	103132	002	1986-06-04	➤ Sign Up	STC.UNM (Albuquerque, NM)	➤ Sign Up	RX		search
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source

International Patent Family for US Patent 9,326,974

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Publication Date
United States of America	2011224141	Sep 15, 2011
United States of America	2014343347	Nov 20, 2014
United States of America	8835506	Sep 16, 2014
Country	Document Number	Publication Date

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.